Pt Kalbe Farma Stock Performance
| PTKFF Stock | USD 0.1 0.01 13.55% |
The company owns a Beta (Systematic Risk) of -0.29, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning PT Kalbe are expected to decrease at a much lower rate. During the bear market, PT Kalbe is likely to outperform the market. At this point, PT Kalbe Farma has a negative expected return of -0.19%. Please make sure to check PT Kalbe's standard deviation and the relationship between the total risk alpha and period momentum indicator , to decide if PT Kalbe Farma performance from the past will be repeated at some future date.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PT Kalbe Farma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's technical and fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 5.2 T | |
| Total Cashflows From Investing Activities | -1.1 T |
PTKFF |
PT Kalbe Relative Risk vs. Return Landscape
If you would invest 11.00 in PT Kalbe Farma on August 25, 2024 and sell it today you would lose (1.49) from holding PT Kalbe Farma or give up 13.55% of portfolio value over 90 days. PT Kalbe Farma is currently producing negative expected returns and takes up 2.8187% volatility of returns over 90 trading days. Put another way, 25% of traded pink sheets are less volatile than PTKFF, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PT Kalbe Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PT Kalbe's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PT Kalbe Farma, and traders can use it to determine the average amount a PT Kalbe's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0663
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PTKFF |
Estimated Market Risk
| 2.82 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PT Kalbe is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PT Kalbe by adding PT Kalbe to a well-diversified portfolio.
PT Kalbe Fundamentals Growth
PTKFF Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PT Kalbe, and PT Kalbe fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PTKFF Pink Sheet performance.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Current Valuation | 6.11 B | |||
| Shares Outstanding | 46.26 B | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 3.56 X | |||
| Revenue | 26.26 T | |||
| EBITDA | 4.54 T | |||
| Cash And Equivalents | 189.29 M | |||
| Total Debt | 490.28 B | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | 2.83 T | |||
| Total Asset | 25.67 T | |||
| Retained Earnings | 10.82 T | |||
| Current Asset | 9.22 T | |||
| Current Liabilities | 2.46 T | |||
About PT Kalbe Performance
By analyzing PT Kalbe's fundamental ratios, stakeholders can gain valuable insights into PT Kalbe's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PT Kalbe has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PT Kalbe has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 12501 people.Things to note about PT Kalbe Farma performance evaluation
Checking the ongoing alerts about PT Kalbe for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PT Kalbe Farma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PT Kalbe Farma generated a negative expected return over the last 90 days | |
| PT Kalbe Farma has some characteristics of a very speculative penny stock | |
| About 58.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing PT Kalbe's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PT Kalbe's stock is overvalued or undervalued compared to its peers.
- Examining PT Kalbe's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PT Kalbe's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PT Kalbe's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PT Kalbe's pink sheet. These opinions can provide insight into PT Kalbe's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PTKFF Pink Sheet analysis
When running PT Kalbe's price analysis, check to measure PT Kalbe's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PT Kalbe is operating at the current time. Most of PT Kalbe's value examination focuses on studying past and present price action to predict the probability of PT Kalbe's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PT Kalbe's price. Additionally, you may evaluate how the addition of PT Kalbe to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |